• Cost and credibility savings gained by shortening the time to submit data to regulatory authorities (The potential savings if 2% fewer compounds fail for safety reasons can $10-$20M for a large biopharmaceutical company).
• More intelligent and broad access to historical information will lead to better decisions.

The potential return on investment for even a 2% improvement in development decisions (i.e. 2% fewer compounds fail for safety reasons) can be dramatic (e.g. large companies with pre-clinical R&D budgets in excess of $1B will save several million dollars in lost effort annually).

• Tremendous cost savings in terms of human resources to access, sort and find needed information on marketed products, particularly in case of litigation.
• Better protection of, access to, and value from vast stores of intellectual property.

  Download Full Project Overview                                                   Contact Us

Previous Page    Back to Project Description    Next Page